Compare Micron Technology, Inc. (MU) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Micron Technology, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Micron Technology, Inc. trades at $1,056.13 (market cap $1.23T), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Micron Technology, Inc. is far larger — about 9.6× Vertex Pharmaceuticals Incorporated's market cap, and Micron Technology, Inc. pays a 0.06% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Micron Technology, Inc. for 48 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| MU | VRTX | |
|---|---|---|
Market Cap | $1.23T | $128.16B |
Volume | 30,214,899 | 806,603 |
Sector | Technology | Health |
52-Week High | $1.21K | $557.96 |
52-Week Low | $181.60 | $407.37 |
Typical Hold Time | 48 Days | 120 Days |
Enterprise Value | $1.19T | $122.29B |
Dividend Yield | 0.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) trades at $1,035.84, down 0.93% today but remains in a strong uptrend with a 500% gain over the past year. The stock exhibits bullish technical signals, supported by robust fundamentals including a 379% YoY revenue surge in fiscal 2026 and consistent earnings beats. Analyst sentiment is overwhelmingly positive, with 83% recommending Buy, citing AI-driven memory demand and strategic customer agreements securing future revenue.
Outlook: Micron is positioned for sustained growth through 2030 due to AI memory demand and supply constraints, but risks include cyclical slowdowns and valuation sensitivity. The consensus price target of $1,590 implies 53% upside, though high volatility and competitive pressures warrant caution for new investments.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
